AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8060436
Drug: Albuterol nebulized
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol nebulized solution 2.5 mg inhaled every 4 hours (Group II)
Trial: 30859944
Drug: Brexpiprazole (flexible-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole (flexible-dose 1-4mg/day)
Trial: 28449955
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral naltrexone (7-day washout period)
Trial: 26284539
Drug: Nonresponders (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders (no treatment intervention specified)
Trial: 26284539
Drug: IL28B CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL28B CC genotype
Trial: 25098489
Drug: Synbiotic [Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic [Lactobacillus acidophilus NCFM (10(9) CFU) and cellobiose (5 g)]
Trial: 23134997
Drug: Lidocaine diluted
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine diluted with normal saline (3 mL of 1% lidocaine + epinephrine in 30 mL of bacteriostatic 0.9% sodium chloride in a 1:10 ratio)
Trial: 23134997
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine (5 mL of 8.4% sodium bicarbonate solution and 50 mL of 1% lidocaine + epinephrine in a 1:10 ratio)
Trial: 17804079
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies (short-term and long-term)
Trial: 14574055
Drug: Clinical score
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical score treatment (Control)
Trial: 10589358
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX)
Trial: 8933780
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate, 200 micrograms once daily
Trial: 1805294
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg/day PO)
Trial: 6425713
Drug: l-tryptophan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-tryptophan (40 mg/kg body weight)
Trial: 31227374
Drug: Septoplasty with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septoplasty with or without concurrent turbinate surgery
Trial: 25041494
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg in 50 ml infusion
Trial: 25041494
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg in 250 ml infusion
Trial: 25041494
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg (50 ml and 250 ml)
Trial: 18455908
Drug: rTMS (1Hz)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS (1Hz) with exposure therapy
Trial: 18455908
Drug: Sham (placebo)
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham (placebo) with exposure therapy
Trial: 17485893
Drug: Pioglitazone hydrochloride
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone hydrochloride (15 mg or 30 mg)
Trial: 17485893
Drug: Glibenclamide (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (1.25 mg or 2.5 mg)
Trial: 15001191
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg olmesartan
Trial: 15001191
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg olmesartan
Trial: 15001191
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg olmesartan
Trial: 15001191
Drug: olmesartan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan (all doses)
Trial: 11260006
Drug: F6‐1,25(OH)2D3 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F6‐1,25(OH)2D3 (5 microg in 0.1 g of petrolatum)
Trial: 11260006
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 g of petrolatum)
Trial: 11260006
Drug: F6‐1,25(OH)2D3 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F6‐1,25(OH)2D3 (50 microg g‐1 of petrolatum) applied to all lesions
Trial: 7999600
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate solution (1 mg/ml)
Trial: 7999600
Drug: Calcipotriol solution
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol solution (50 micrograms/ml)
Trial: 31325822
Drug: Multicomponent cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent cognitive-behavioral therapy (adapted for lower socioeconomic groups or standard) + 8 weeks of nicotine patches
Trial: 26111351
Drug: Prostvac-VF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostvac-VF vaccine followed by docetaxel chemotherapy (Arm A, n = 6)
Trial: 26111351
Drug: Docetaxel chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel chemotherapy alone (Arm B, n = 2)
Trial: 23424237
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily with bendroflumethiazide 1.25 mg (CB)
Trial: 23424237
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily with placebo (CP)
Trial: 21894078
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Tramadol mixed with 20 ml of sugar syrup
Trial: 31809408
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Tramadol
Trial: 17115390
Drug: 0.2 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 per cent glyceryl trinitrate (GTN) ointment
Trial: 17115390
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (petroleum jelly)
Trial: 8169417
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment for 10 days
Trial: 8169417
Drug: Antimicrobial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial treatment alone
Trial: 2901037
Drug: Single perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single perioperative course of adjuvant combination chemotherapy beginning within 36 hours of mastectomy
Trial: 2901037
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of conventionally timed adjuvant chemotherapy starting 25 to 32 days after operation
Trial: 2901037
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival differences favored the longer treatments
Trial: 25302462
Drug: Intravascular low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular low-level laser therapy (LLLT)
Trial: 20297611
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) 50 microg
Trial: 20297611
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) 100 microg
Trial: 20297611
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) 200 microg
Trial: 20297611
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl spray (INFS) (all doses)
Trial: 12412840
Drug: Dronabinol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (2.5 mg)
Trial: 2479252
Drug: Hydrochlorothiazide 100
RxNorm normalized name: hydrochlorothiazide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 100 mg daily
Trial: 31923242
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of oral Mg++ citrate (n = 66)
Trial: 31923242
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Mg++ and placebo)
Trial: 22659994
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 16 mg galantamine plus 20 mg memantine
Trial: 22659994
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg galantamine alone
Trial: 22659994
Drug: Galantamine (as
RxNorm normalized name: benzgalantamine (as gluconate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (as part of the combination regimen or as mono treatment)
Trial: 12471291
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy treatment (McConnell-based)
Trial: 8120307
Drug: Influenza hemagglutinin-diphtheria
RxNorm normalized name: Bordetella pertussis filamentous hemagglutinin vaccine, inactivated / Bordetella pertussis pertactin vaccine, inactivated / Bordetella pertussis toxoid vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Infanrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza hemagglutinin-diphtheria toxoid conjugate vaccine (HA-D)
Trial: 8120307
Drug: Influenza hemagglutinin-subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza hemagglutinin-subunit vaccine (HA)
Trial: 2517008
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg
Trial: 2571296
Drug: Reference alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference alpha 2‐agonists
Trial: 31901705
Drug: COMBO450 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBO450 (450 mg of encorafenib QD + 45 mg of binimetinib BID)
Trial: 31901705
Drug: ENCO300 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENCO300 (300 mg of encorafenib QD)
Trial: 31901705
Drug: VEM (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEM (960 mg of vemurafenib BID)
Trial: 30640775
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of TXA 100 mg/1 mL
Trial: 30640775
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of TXA 100 mg/1 mL in anticoagulant subgroup
Trial: 30640775
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) in anticoagulant subgroup
Trial: 19491837
Drug: Baclofen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (3 x 20 mg) during PPI treatment
Trial: 19491837
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during PPI treatment
Trial: 8602379
Drug: clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clarithromycin 250 mg
Trial: 8602379
Drug: doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 100 mg twice/day for 7 days
Trial: 2813982
Drug: Ambroxol 75
RxNorm normalized name: ambroxol 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 75 mg once a day after breakfast for 30 days
Trial: 1069366
Drug: i.v. pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pulse doses of 13‐nle‐m (0.05, 0.1, 0.2, and 0.4 mug/kg)
Trial: 1069366
Drug: i.v. bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus injections of 0.6 mug/kg pentagastrin
Trial: 1069366
Drug: i.v. infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusions of 13‐nle‐m (0.1, 0.2, and 0.4 mug/kg‐h)
Trial: 1069366
Drug: i.v. pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pulse dose of 0.1 mug/kg 13‐nle‐m with concomitant atropine
Trial: 29493409
Drug: Brief Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive-Behavioral Therapy (CBT)
Trial: 22460459
Drug: Melatonin 2x5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2x5 mg daily
Trial: 17601560
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of sustained-release morphine sulfate
Trial: 17601560
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of sustained-release morphine sulfate
Trial: 9521487
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g or 6 g, intravenous infusion for 30 min)
Trial: 9521487
Drug: L-arginine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (10 microM-2.5 mM, in vitro preincubation)
Trial: 7543691
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin (6 g per liter of extracted liquid)
Trial: 7543691
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 (6 g per liter of extracted liquid)
Trial: 30325178
Drug: Pegvisomant (PEGV),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (PEGV), average daily dose increased from 12.8 mg (year 1) to 18.9 mg (year 10)
Trial: 26797837
Drug: Neoadjuvant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiochemotherapy (50 Grays over six weeks and four cycles of mFOLFOX6 chemotherapy)
Trial: 17126918
Drug: Ribosomal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribosomal immunotherapy (one tablet a day, 8 days a month for 3 months)
Trial: 11313088
Drug: Antidepressants (pharmacotherapy)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (pharmacotherapy)
Trial: 11313088
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (antidepressants + 16 sessions of Short Psychodynamic Supportive Psychotherapy)
Trial: 9138281
Drug: 25 mg,
RxNorm normalized name: 0.25 MG, 0.5 MG Dose 3 ML Ozempic 0.68 MG/ML Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, 100 mg or 300 mg lamivudine daily for 6 months
Trial: 2908102
Drug: Cabergoline 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.3 mg
Trial: 2908102
Drug: Cabergoline 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.6 mg
Trial: 2908102
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg (Control)
Trial: 2908102
Drug: Cabergoline 0.3-0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.3-0.6 mg (repeated administration)
Trial: 2908102
Drug: Cabergoline 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.6 mg (increased dose)
Trial: 2908102
Drug: Cabergoline (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (any dose)
Trial: 29210921
Drug: Probiotics administration
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administration during late pregnancy and first 6 months of life
Trial: 29210921
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration during late pregnancy and first 6 months of life
Trial: 28175315
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide
Trial: 28175315
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide in HIV co-infected patients on efavirenz-based ART
Trial: 28175315
Drug: Moxifloxacin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin alone (single dose) after TB treatment completion
Trial: 12966542
Drug: Vaccine therapy
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine therapy (n = 13)
Trial: 12966542
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control, n = 6)
Trial: 8218760
Drug: TJ-43 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-43 (2.5 g three times daily)
Trial: 25129395
Drug: Fluralaner (25-56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner (25-56 mg/kg; Bravecto™)
Trial: 25129395
Drug: Spinosad (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinosad (30-60 mg/kg; Comfortis®) with amitraz collar (9%; Preventic®)
Trial: 22944002
Drug: l‐dopa 'on'/DBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐dopa 'on'/DBS 'on'
Trial: 22944002
Drug: l‐dopa 'on'/DBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐dopa 'on'/DBS 'off'
Trial: 22944002
Drug: l‐dopa 'off'/DBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐dopa 'off'/DBS 'on'
Trial: 22944002
Drug: l‐dopa 'off'/DBS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐dopa 'off'/DBS 'off'
Trial: 22944002
Drug: Combined effect
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined effect of DBS and l‐dopa administration
Trial: 22944002
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment conditions combined
Trial: 20540847
Drug: Aripiprazole (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (2.5-10 mg/d)
Trial: 20540847
Drug: Tiapride (25-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (25-400 mg/d)
Trial: 2697693
Drug: Ayurvedic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic preparation (Aegle marmelos correa plus Bacopa monniere Linn)
Trial: 2697693
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (clidinium bromide, chlordiazepoxide and isaphaghulla)
Trial: 2697693
Drug: Ayurvedic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic preparation
Trial: 2697693
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy and Ayurvedic therapy
Trial: 2697693
Drug: Both forms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both forms of therapy (Ayurvedic and Standard)
Trial: 7410127
Drug: Intravenous Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Methotrexate (25 mg every third day for 5 doses) followed by definitive radiotherapy
Trial: 26936776
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment for 6 weeks
Trial: 25208127
Drug: Angiotensin-(1-7) infusion
RxNorm normalized name: Angiotensin (1-7)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-(1-7) infusion (0.27, 0.9, and 2.7 ng/kg per min)
Trial: 21822162
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 70 mg daily (35 mg × 2)
Trial: 9675609
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement (20 ml/day)
Trial: 9675609
Drug: Soybean phosphatidylcholine
RxNorm normalized name: Soybean Phosphatidylcholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean phosphatidylcholine (PC) (25 g/day)
Trial: 8008712
Drug: Small intestinal
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small intestinal infusion (SI) of benazepril hydrochloride (20 mg)
Trial: 8008712
Drug: Colonic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonic infusion (COLON) of benazepril hydrochloride (20 mg)
Trial: 8008712
Drug: Oral bolus
RxNorm normalized name: phenylbutazone 1000 MG Oral Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bolus solution (ORAL) of benazepril hydrochloride (20 mg)